NEW YORK, May 11, 2023 /PRNewswire/ — Terran Biosciences (“Terran”), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has announced the publication of four PCT patent applications covering novel improvements to the empathogens methylone (also known as bk-MDMA or MDMC), ethylone, MDEA (also known as MDE), MDAI…
Source